John Boris
John Boris
avenues beyond cases court decision exhausted february hears largely patent point regain rejection remains supreme
The Supreme Court only hears patent cases approximately 7% of the time. Therefore, the Supreme Court's rejection of the case was largely anticipated and the Appellate court decision remains in place. Merck has exhausted all avenues to regain U.S. exclusivity beyond February 2008, at which point generics are expected.
anchored attractive believe current downside levels limited offering risk
We believe the downside risk from current levels is limited anchored by Merck offering an attractive 4.4% dividend.